Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

24.37USD
23 Feb 2017
Change (% chg)

-- (--)
Prev Close
$24.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
123,295
52-wk High
$26.01
52-wk Low
$9.40

Select another date:

Wed, Feb 22 2017

BRIEF-Esperion posts Q4 loss per share $1.29

* Esperion provides bempedoic acid development program update; reports fourth quarter and full year 2016 financial results

BRIEF-Esperion completes enrollment of pivotal phase 3 long-term safety and tolerability study of Bempedoic Acid

* Esperion completes enrollment of pivotal phase 3 long-term safety and tolerability study of bempedoic acid in patients with hypercholesterolemia

BRIEF-Esperion Therapeutics reports qtrly loss per share $0.77

* Esperion Therapeutics Inc says expects full-year net cash used in operating activities in 2016 will be approximately $65 million

BRIEF-Bempedoic Acid Global phase 3 clinical program to include patients on any Statin at any dose

* Bempedoic acid global phase 3 clinical program to include patients on any statin at any dose

BRIEF-BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics

* BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing Source text for Eikon: Further company coverage:

Select another date:

More From Around the Web